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Empagliflozin in heart failure — new facts
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The article by Komorowska et al. presented the current 
state of knowledge regarding the effect of empagliflozin 
on the cardiovascular system based on the description of 
a clinical case of heart failure with reduced ejection fra-
ction (HFrEF) and concomitant diabetes [1]. The patient in 
question was burdened with numerous cardiovascular risk 
factors and comorbidities. The patient obtained 26 points in 
the MAGGIC (Meta-Analysis Global Group in Chronic Heart 
Failure) scale, which translates into a high annual mortality 
of 17.5% and a high three-year death rate of 39.7%.
Currently, the patient remains under observation which 
has been maintained for 15 months since the re-onset of 
empagliflozin therapy. During this time, there has been no 
hospitalisation for exacerbation of heart failure (HF) or for 
any other reason, there were no outpatient visits requiring 
an increase doses in diuretics, and there was no need to 
modify the therapy used. It is worth stating that the patient 
has been optimally treated for HFrEF since the last hospi-
talisation in May 2018, including with the drug sacubitril/ 
/valsartan at a target dose of 97/103 mg bis die (BD).
Empagliflozin is well tolerated in this patient. There 
have been no incidents of hypoglycaemia or ketoacidosis. 
No gastrointestinal complaints or fungal infections have 
been recorded, and kidney function has not deteriorated.
Empagliflozin is one of a new group of sodium and 
glucose co-transporter type 2 (SGLT2) inhibitor drugs dedi-
cated to diabetes therapy. The drug came to the attention 
of cardiologists after the publication of the results of the 
EMPAREG-OUTCOME study [2, 3]. Empagliflozin is today 
the most selective and best-understood SGLT2 inhibitor.
It is known from the EMPAREG-OUTCOME study that, 
in diabetic patients, empagliflozin improves the prognosis 
compared to a placebo in reducing the risk of total mortality, 
cardiovascular mortality, three-point MACE (major adverse 
complicating events i.e. non-fatal myocardial infarction, 
non-fatal stroke and cardiovascular death) and the risk 
of HF hospitalisation [3], regardless of the initial load of 
myocardial infarction, stroke and cardiovascular risk cal-
culated according to the TIMI (Thrombolysis in Myocardial 
Infarction) Risk Score for secondary prevention [4] and 
regardless of glycaemic status [5]. Both high- and low-risk 
patients have an improved prognosis.
The clinical benefit of empagliflozin therapy has also 
been documented in terms of greater life expectancy for 
all age groups [6]. However, patients aged 45 and under, 
for whom the survival improvement has been calculated 
to be 4.5 years, benefit the most. According to the data 
produced by the EMPAREG-OUTCOME study, the patient in 
question has a chance of prolonging life by 3.1 years [6].
Real-world evidence (RWE) data from the EMPRISE 
(Empagliflozin Comparative Effectiveness and Safety) study 
including 35,000 patients has supplemented the results 
of EMPAREG-OUTCOME, and confirmed the efficacy and 
safety of empagliflozin therapy compared to the dipeptidyl 
peptidase 4 (DPP-4) inhibitor — sitagliptin, which is an opti-
mal comparator due to the similar profile of hypoglycaemic 
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effect and neutral effect on cardiovascular endpoints [7]. 
The use of empagliflozin at both doses was associated 
with a reduced risk of HF hospitalisation in routine clinical 
practice compared to sitagliptin [hazard ratio (HR) 0.56, 
95% confidence interval (CI) 0.43–0.73, p < 0.0001). The 
effect of empagliflozin on reducing the risk of hospitalisa-
tion due to HF was similar in patients with and patients 
without confirmed cardiovascular disease.
The results of studies conducted so far have allowed the 
inclusion of SGLT2 inhibitors in the 2016 recommendations 
of the European Society of Cardiology (ESC) for HF [2], the 
2018 recommendations of the American College of Cardio-
logy (ACC) for risk reduction in patients with diabetes and 
cardiovascular diseases [8], the 2019 expert position of 
the ESC Heart Failure Association [9], and the 2019 ACC/ 
/American Heart Association (AHA) guidelines for primary 
prevention of cardiovascular diseases [10].
Further studies dedicated to patients with HF, both 
with and without diabetes, will determine the significance 
and role of empagliflozin and other SGLT2 inhibitors in the 
therapy of patients with HF.
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